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Background: Understanding the contextual factors that influence the dissemination and
implementation of evidence-based chronic disease prevention (EBCDP) interventions
in public health settings across countries could inform strategies to support the
dissemination and implementation of EBCDP interventions globally and more effectively
prevent chronic diseases. A survey tool to use across diverse countries is lacking. This
study describes the development and reliability testing of a survey tool to assess the stage
of dissemination, multi-level contextual factors, and individual and agency characteristics
that influence the dissemination and implementation of EBCDP interventions in Australia,
Brazil, China, and the United States.
Methods: Development of the 26-question survey included, a narrative literature review
of extant measures in EBCDP; qualitative interviews with 50 chronic disease prevention
practitioners in Australia, Brazil, China, and the United States; review by an expert panel
of researchers in EBCDP; and test-retest reliability assessment.
Results: A convenience sample of practitioners working in chronic disease prevention
in each country completed the survey twice (N = 165). Overall, this tool produced good
to moderately reliable responses. Generally, reliability of responses was higher among
practitioners from Australia and the United States than China and Brazil.
Conclusions: Reliability findings inform the adaptation and further development of this
tool. Revisions to four questions are recommended before use in China and revisions to
two questions before use in Brazil. This survey tool can contribute toward an improved
understanding of the contextual factors that public health practitioners in Australia,
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Brazil, China, and the United States face in their daily chronic disease prevention
work related to the dissemination and implementation of EBCDP interventions. This
understanding is necessary for the creation of multi-level strategies and policies that
promote evidence-based decision-making and effective prevention of chronic diseases
on a more global scale.
Keywords: chronic disease, reliability, evidence-based practice, implementation, international health

INTRODUCTION

This study provides a detailed overview of the development
and test-retest reliability of a survey tool to measure the
stage of dissemination, multi-level contextual factors, and
individual and agency characteristics that influence the D&I
of EBCDP interventions in Australia, Brazil, China, and the
United States. These countries were chosen for several reasons
including, their leadership in distinct regions of the world
(16–20), differences on contextual variables of interest (e.g.,
sociocultural, political/economic) (21), and high prevalence of
chronic diseases (22). The World Health Organization reports
from 2014 showed that the large majority of deaths in each
of the four countries was due to chronic diseases (91% in
Australia, 88% in the United States, 87% in China, and 74%
in Brazil) (22). Further, based on the few studies of the
D&I of EBCDP from Brazil and China (23, 24), compared
with the many from Australia and the United States (25–29),
Brazil, and China were selected as countries likely in earlier
stages of dissemination of EBCDP than Australia and the
United States.

Chronic diseases are a threat to global health, in developed
and developing countries alike, accounting for 60% of deaths
worldwide (1). The medical costs and loss of productivity related
to chronic diseases are a great financial burden to individuals
and economies (1). Evidence-based chronic disease prevention
(EBCDP) interventions are effective tools for preventing chronic
diseases (2). However, studies among U.S. and European public
health practitioners indicate that only 56–64% of chronic
disease prevention interventions currently in use are evidencebased (3, 4), while estimates of use of EBCDP interventions
in lower and middle income countries are unknown. Studies
in Australia and the United States have identified multilevel contextual factors that influence the dissemination and
implementation (D&I) of EBCDP interventions. Examples of
these contextual factors include individual- and agency-level
capacity characterized by the training, structure, material and
human resources at hand that hinder or facilitate the use of
EBCDP interventions (2, 5–7). Additional work has addressed
some of the contextual barriers by training practitioners on the
evidence-based decision-making process, specifically clarifying
the reasons for selecting EBCDP interventions and outlining
how to find the interventions and resources to support effective
implementation and quality improvement (3, 4, 7). These studies
report increases in the D&I of EBCDP interventions among
practitioners who attended the trainings. Research on Canadian
public health departments has identified tailored messaging as
an effective method for promoting the D&I of evidence-based
interventions (8), and examined the pathways through which
evidence is shared through organizational systems (9). These
contextually specific findings inform next steps in addressing
barriers and promoting evidence-based decision-making across
the Canada. Little is known about these contextual factors
that influence the D&I of EBCDP interventions in developing
countries, nor the similarities and differences of contextual
factors across countries. Several studies call for global strategies
to improve the D&I of EBCDP interventions in order to more
effectively reduce chronic diseases around the world (10–12).
Reviews of measures used to assess the contextual factors that
influence the D&I of EBCDP interventions highlight a lack
of psychometric testing of the existing measures and room
for improvement among those that have been tested (13–15).
To assess cross-country contextual factors and inform globallyfocused recommendations for facilitating the D&I of EBCDP
interventions, a single survey tool that can be used across
multiple, diverse countries is needed.
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MATERIALS AND METHODS
Survey Tool Development
Development of the 26-question survey occurred in several
stages. First, a guiding framework was developed based on
previous work (30, 31) of the research team (see Figure 1).
This framework informed subsequent stages of survey tool
development, ensuring that qualitative interview questions and
initial survey drafts were literature-based and comprehensive
from the outset.
Second, a narrative literature review of extant measures in
EBCDP was carried out in order to identify relevant questions
and gaps in the D&I of EBCDP literature (2, 6, 31–35). Third,
between February and July 2015 semi-structured interviews
of public health practitioners in Australia (n = 13), Brazil
(n = 9), China (n = 16), and the United States (n = 12) were
conducted by trained researchers. Practitioners were identified
through purposive sampling based on their employment at
agencies responsible for the prevention of chronic disease in each
country, including community health services, regional health
departments, and non-government organizations (Australia);
the ministry of health and local health departments (Brazil);
hospitals, community health centers, and the Centers for Disease
Control and Prevention (China); and local health departments
(United States). The interviews were performed in English,
Chinese, or Portuguese, audio recorded, transcribed, translated
to English by two bi-lingual research team members (n = 25)
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FIGURE 1 | Factors affecting the stages of dissemination of evidence-based programs and policies for chronic disease prevention.

a network of community hospitals received one email and
one follow-up telephone call requesting participation in the
electronic survey (87% response rate). All surveys were delivered
by an email embedded link and completed electronically. Upon
completion of the survey, all respondents were asked to retake the survey two to three weeks later for test-retest reliability
testing purposes. This process was repeated until each respondent
to the survey had been contacted twice, requesting them to
retake the survey. Calculating Cohen’s kappa and Intraclass
correlation coefficients (ICC) ranging from 0.50 to 0.70 require
a sample size of 25–50 test-retest pairs, respectively (38), thus
25 pairs were the minimum, but 50 pairs were the goal. During
data collection, political events in Brazil affected the work
lives of many Brazilian chronic disease practitioners and made
recruitment of Brazilian practitioners extraordinarily difficult
(39, 40). The data collection period was extended for research
team investigators in Brazil in order to reach the minimum
sample size.
This study was carried out in accordance with the committee
responsible for human experimentation (institutional and
national) and with the World Medical Association’s Declaration
of Helsinki with informed consent from all subjects. After
reading the electronic informed consent document, subjects
indicated their consent by selecting a radial button at the
bottom of the informed consent document that read, “I
consent to participate in this research study.” Additional written
documentation of consent was waived and the protocol was
approved by The University of Melbourne Human Ethics
Committee, Pontifica Universidade Catolica do Parana Research
Ethics Committee, The Hong Kong Polytechnic University
Human Ethics Committee of the Faculty of Health and Social

when appropriate, and analyzed using deductive, hierarchical
coding in NVivo version 10.
Forth, drafts of the survey underwent expert review by
13 chronic disease prevention researchers and were translated
forward and backward to Chinese and Portuguese from English.
Survey questions were organized into one of the five stages
of dissemination or as multi-level contextual factors seen
in Figure 1. Individual and agency characteristics were also
included. Seven response items were deemed non-applicable or
inappropriate for China contexts, but were included in the survey
for the other three countries. These response items and the
resulting tool can be found in Table 1.
Fifth, research team members in each country recruited public
health practitioners working in chronic disease prevention,
primarily on the local and regional levels, in each of the
four countries to complete the survey. Samples of practitioners
from various regions of each country were identified through
national databases and networks of chronic disease prevention
practitioners between November 2015 and April 2016. Public
health systems across countries varied so much that there was no
equivalent sampling method that worked for all four countries.
In the United States, a stratified (by region) random sample of
chronic disease prevention practitioners from a national database
received up to three emails and two follow-up telephone calls
requesting participation in the electronic survey (58% response
rate). In Australia, up to two emails requesting participation in
the electronic survey were sent to all chronic disease practitioners
in a national registry (18% response rate). In Brazil, the same
protocol as was followed in the United States was used, but with
an additional follow-up telephone call (46% response rate). In
China, a convenience sample of practitioners working within
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TABLE 1 | Factors influencing the dissemination and implementation of evidence-based chronic disease prevention across four countries: a survey tool.
Questions

Response options

Awareness
•
•
•
•
•

Not at all knowledgeable
Slightly knowledgeable
Somewhat knowledgeable
Moderately knowledgeable
Extremely knowledgeable

Definition: Evidence-based interventions are those that several studies have found to
be effective at preventing chronic disease. Repositories are collections of
evidence-based interventions (e.g., Guide to Community Preventive Services) (US),
Health-Evidence.org (Australia), Cochrane Collaboration (US, Australia).
2. I have used repositories to find evidence-based interventions: (select one)

•
•
•
•

In none of my programmatic areas
In a few of my programmatic areas
In many of my programmatic areas
In all of my programmatic areas

3. Staff at my agency use repositories of evidence-based interventions:
(select one)

•
•
•
•

In none of my programmatic areas
In a few of my programmatic areas
In many of my programmatic areas
In all of my programmatic areas

4. When you make decisions about such things as program planning and
implementation, policy development, or funding, which of the following are important
to you? (select the top three)

•
•
•
•
•
•
•
•
•
•
•
•
•

Support from leadership at my agency
Support from elected officials
Support from community partnerships
Recommendations from the funding agency
Colleagues are using the intervention
Available resources (program dollars and staff)
How easy the intervention or policy is to implement
Evidence regarding the effectiveness of the intervention
Health planning tools (e.g., MAPP or Health People 2010)
Relevance of the intervention to the population of interest
Seriousness of the health problem
Other, please specify ______
Not applicable

5. What avenues do you use to learn about the current study findings on
evidence-based chronic disease prevention interventions? (select all that apply)

•
•
•
•
•
•
•
•
•
•
•
•
•

Academic journals
Conferences
Email alerts
Evidence-based repositories
Facebook
Fundersa
Government agency staff
Government reports
Internet search engines
Listservs/Newsletters/Online forums
Media campaigns/Media interviews
Networks
Partnerships (e.g., with universities, health departments, professional
associations)
Policy briefsa
Press releases
Stakeholdersa
Technical assistance/Data liaison
Trainings/Workshops/Meetings within my agency
Webinars
Other, please specify ______
None

• Evidence-based public health is defined as: “the process of integrating
science-based interventions with community preferences to improve the health of
populations” (36).
1. With this definition in mind, how knowledgeable are you with evidence-based
processes? (select one)
Adoption

•
•
•
•
•
•
•
•
6. For which avenues would you like additional access? (select all that apply)

Same responses as #13

Implementation
7. Approximately what percentage of programs supported by your agency would you
say are evidence-based?

Fill in the blank 0–100%

8. As you think about the future, what is one thing you would change to help you
implement evidence-based chronic disease prevention interventions?

Fill in the blank

(Continued)
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TABLE 1 | Continued
Questions

Response options

Maintenance
Quality improvement (QI) refers to ongoing formal assessments of the effectiveness
and quality of public health chronic disease prevention efforts. (37).
Some examples of quality improvement processes include: Results-based
accountability (RBA), Community Health Improvement Plan (CHIP),
Plan-Do-Study-Act (PDSA), and Plan-Do-Check-Act.
9. Staff at my agency use quality improvement processes: (select one)

•
•
•
•

10. In your opinion, how often do programs end that should have continued? (i.e.,
end without warrant) (select one)

• Never
• Sometimes
• Often

11. When you think about public health programs that have ended, what are the
most common reasons for programs ending? (Select the top three)

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

12. In your opinion, how often do programs continue that should have ended? (i.e.,
continue without warrant) (select one)

• Never
• Sometimes
• Often

13. When you think about public health programs that continued that should have
ended, what are the most common reasons for their continuation? (i.e., continue
without warrant) (Select the top three)

•
•
•
•
•
•
•
•
•
•
•
•
•
•

Program was never evaluated
Sustained support from leaders in your agency
Sustained support from the general public
Sustained support from policymakers
Prohibitive costs of starting something new
Absence of alternative options
Sustained funding
Presence of a program champion
Program was considered evidence-based
Program was low-cost
Program was easy to maintain
Other, please specify ______
I do not know
Not applicable

14. Which of the following are personal barriers that make it harder for you to select
and implement evidence-based chronic disease prevention interventions? (Select all
that apply)

•
•
•
•
•
•
•
•
•
•

Not being an expert on relevant issues
Lack of confidence in finding data and statistics
Lack of skills to develop evidence-based interventions
Lack of confidence in carrying out evidence-based interventions
Lack of decision-making authority
Low value of evidence-based approaches
Workload is too heavy/not enough time
Overwhelmed by task
Other, please specify ______
None

15. Which of the following are agency-level barriers that make it harder for you to
select and implement evidence-based chronic disease prevention interventions?
(Select all that apply)

•
•
•
•

Poor understanding of evidence-based approaches
Culture/climate is not supportive of change/new ideas
No existing policies to support evidence-based approaches
Agency does not provide training in evidence-based approaches

In none of my programmatic areas
In a few of my programmatic areas
In many of my programmatic areas
In all of my programmatic areas

Program was never evaluated
Program was evaluated but did not demonstrate impact
Opposition/lack of support from leaders in my agency
Opposition/lack of support from the general public
Opposition/lack of support from policy makers
Funding diverted to a higher priority program
Grant funding ended
Change in political leadership
Insurance funding/coverage ended
Program was adopted or continued by other organizations
A program champion departed
Program was not evidence-based
Program was expensive
Program was challenging to maintain
Other, please specify ______
I do not know
Not applicable

Contextual factors

(Continued)
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TABLE 1 | Continued
Questions

Response options
•
•
•
•
•
•
•

Staff/leaders lack formal training in evidence-based approaches
Lack of access to resources (e.g., computer, Internet)
Not enough funding
Low priority placed on chronic disease prevention
No systems to ensure interventions are evidence-based
Not enough staff
Beliefs that evidence-based interventions are too difficult
implement/sustain
• Other, please specify ______
• None

to

16. Which of the following are community-level barriers that make it harder for you to
select and implement evidence-based chronic disease prevention interventions?
(Select all that apply)

• Lack of access to repositories/databases of scientific studies
• Lack of partnership between agency and community
• Community members’ needs compete with evidence-based
recommendations
• Catering to preferences of fundersa
• Low priority placed on chronic disease prevention
• Other, please specify ______
• None

17. Which of the following are sociocultural barriers that make it harder for you to
select and implement evidence-based chronic disease prevention interventions?
(Select all that apply)

• Distrust of scientific data in the populations served
• Community
cultural
practices
conflict
with
evidence-based
recommendations
• Not enough relevant evidence for populations served
• Serving a rural setting where data are lackinga
• Serving a highly disadvantaged population
• Serving a population that speaks a language different from the majoritya
• Evidence is presented in a language I do not understand
• Other, please specify ______
• None

18. Which of the following are political/economic barriers that make it harder for you
to select and implement evidence-based chronic disease prevention interventions?
(Select all that apply)

• Political leaders not providing enough support
• Funding changes that occur with changes in political leadership
• Political climate conflicts with evidence-based chronic disease prevention
recommendations
• Health care system does not support evidence-based chronic disease
prevention
• Other, please specify ______
• None

19. For which of the following skills would you like additional technical support or
training? (Check all that apply)

• Prioritizing program and policy options
• Quantifying the public health issue using descriptive epidemiology (e.g.,
concepts of person, place, time)
• Using quantitative evaluation approaches (e.g., surveillance or surveys)
• Using qualitative evaluation approaches (e.g., focus groups, key informant
interviews)
• Developing an action plan for achieving goals
• Defining the health issue according to the community’s needs and assets
• Adapting interventions for different communities and settings
• Using economic data in the decision making process
• Communicating research to policy makers
• Other, please specify ________
• None

Individual and agency characteristics
20. What is your gender? (select one)

•
•
•
•

Male
Female
Other
Prefer not to answer

21. What is your age? (select one)

•
•
•
•
•
•

21–29
30–39
40–49
50–59
60 and over
Prefer not to answer
(Continued)
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TABLE 1 | Continued
Questions

Response options

22. What degree/credentials do you hold? (Check all that apply)

•
•
•
•
•
•
•
•
•
•
•
•

BS/BA
CHES
Certified Health Educator (in Diabetes, Asthma, etc.)
RN or RD
MS or MSc
MPH or MSPH
MA
Other Master’s degree
NP
MO or DO
PhD, DrPH, ScD
Other, please specify ______

23. Though you may work in several capacities, how do you best describe your
primary position? (select one)

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Academic Researcher
Academic Educator
Community Health Nurse
Department Head
Division or Bureau Head/ Division Deputy
Director
Epidemiologist
Health Educator
Nutritionist/Dietician
Physician
Program Manager/Administrator/Coordinator
Program Planner/ Evaluator
Public Health Specialist
Social Worker
Statistician
Other, please specify ______

24. The agency in which I work has the following number of employees. (select one)

•
•
•
•
•
•
•

0–50
51–100
101–200
201–400
401–800
>800
I do not know

25. The size of the population my agency serves is has the following number of
people. (select one)

•
•
•
•
•
•
•
•
•
•

0–24,999
25,000–49,999
50,000–74,999
75,000–99,999
100,000–149,999
150,000–199,999
200,000–299,999
300,000–399,999
400,000+
I do not know

26. Is there anything else you would like to share on the topic of evidence-based
chronic disease prevention? Please specify

Fill in the blank

a This

item was not applicable and not included in the survey for respondents in China.

4, 5, 11, and 13 through 19 was dichotomized to reflect
whether a respondent selected the response option or not.
Cohen’s kappa was run for each of these response options
individually. The mean of all of the Cohen’s kappas for each
question’s set of response options was calculated. Cut-points
for ICC and mean kappa (excellent: ≥0.801; good: 0.601–0.80;
moderate: 0.401–0.60; poor: ≤0.40) were selected based on
recommendations (41, 42), and to aid in the interpretation of
the results. Percentage agreement was also calculated for all
of the aforementioned questions, excluding question 7, which
asked respondents to provide a percentage. Questions for which

Science, and Washington University in St. Louis Institutional
Review Board.

Analyses
Test-retest reliability was examined on the survey questions,
excluding open-ended questions and individual and agency
characteristics. Intraclass correlation coefficients (ICC) were
calculated for questions with ordinal response options (questions
1 through 3, 9, 10, and 12; see Table 1). “I don’t know”
and “not applicable” response options were not included
in the ICC calculations. Each response item for questions
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among practitioners in China: Personal use of repositories to find
evidence-based interventions; Workplace staff use of repositories
to find evidence-based interventions; Frequency that programs
end that should have continued; and Frequency that programs
continue that should have ended. Two of those questions
(Workplace staff use of repositories to find evidence-based
interventions, and Frequency that programs end that should
have continued) produced less than moderately reliable responses
among practitioners from Brazil based on both measures of
reliability as well.

mean kappa was calculated, mean percentage agreement was
also calculated. Cut-points for percentage agreement included:
excellent: 89.5–100%; good: 74.5–89.4%; moderate: 60–74.4%;
and poor: <60%. All analyses were conducted in Stata
version 14.

RESULTS
There were 400 survey respondents total and 165 of them took
the survey twice for test-retest reliability purposes (N = 39
from Australia; N = 27 from Brazil; N = 45 from China;
N = 54 from the United States). The test-retest respondents
were all public health practitioners (e.g., nutritionist/dietician,
coordinator, community health nurse) working in chronic
disease prevention. Public Health Specialist was added as a
primary employment position option post hoc, in order to capture
a common “other” response provided by practitioners from
Brazil. Respondents were primarily female (79%) between 30
and 49 years old (53%). The mean survey completion time
varied by country, with Brazil having the longest (33.2 min
± 27.8), followed by the United States (17.72 min ± 13.4),
Australia (16.6 min ± 10.0), and China (13.8 min ± 10.5). The
mean number of days between test and retest was greatest in
Brazil (46.4 ± 28.5), followed by Australia (39.0 ± 2.8), China
(23.7 ± 7.6) and the United States (21.0 ± 9.1). Table 2 shows
frequency counts for each response option by country, the first
time respondents completed the survey. Item responses vary in
prevalence from zero endorsements to endorsement from a large
majority of a county’s sample.
The test-retest reliability coefficients and percentage
agreement by question and country appear in Table 3. Of
the seven questions with ordinal response options assessed using
ICC, six and seven demonstrated good to moderate reliability
among practitioners from Australia and the United States,
respectively, whereas three questions among practitioners from
Brazil and China demonstrated good to moderate reliability. Six
of those seven questions were also assessed using percentage
agreement. Six and five of the questions demonstrated good
to moderate percentage agreement among practitioners from
Australia and the United States, respectively, whereas three
questions among practitioners from Brazil and one among
practitioners from China demonstrated moderate percentage
agreement at best.
Of the 11 questions whose response options were
dichotomized and assessed using mean Cohen’s kappa, few
questions among practitioners across all four countries showed
moderate mean reliability at best (Australia, N = 2; Brazil,
N = 1; China, N = 1; United States, N = 3). Mean percentage
agreement told a different story for these 11 questions. All but
one question showed good mean percentage agreement among
practitioners from Australia and the United States. Seven and
five questions showed good mean percentage agreement among
practitioners from Brazil and China, respectively. The remaining
of the 11 questions across the countries showed moderate mean
percentage agreement.
The following four questions produced less than moderately
reliable responses based on both ICC and percentage agreement

Frontiers in Public Health | www.frontiersin.org

DISCUSSION
The development and reliability testing of this survey tool
are important early steps toward facilitating population-level
research that can increase our knowledge of country-specific
and cross-country contextual factors that influence the D&I
of EBCDP interventions and, in turn, begin to inform more
global strategies for improving the D&I of EBCDP. This study,
novel in its common methods across countries, showed that
the measurement tool produced moderate to good reliability of
responses, with at least one measure of reliability, among 14 of
the 18 questions across all four countries.
Reliability findings inform the adaptation and further
development of this tool. For example, the authors recommend
revising the four questions pertaining to personal and workplace
staff use of repositories for finding evidence-based interventions
and frequency that programs end or continue without warrant
before further use among practitioners in China and Brazil.
The poor reliability of responses produced from these questions
among practitioners from Brazil and China reflect a difference
in how they relate to the content of the questions, compared
with practitioners from Australia and the United States. This
difference may highlight meaningful differences within contexts
with respect to D&I processes and structures. For instance,
practitioners in countries for which EBCDP is in an earlier
stage of dissemination tend to be less knowledgeable about key
concepts of EBCDP, making the questions conceptually more
difficult and in turn negatively influencing the reliability of their
responses (43). Another potential contributing factor to the
lower reliability among responses from practitioners in Brazil
and China is that the survey tool had to be translated from
English to Chinese and Portuguese. Tanzer and Sim review
international guidelines on translating and adapting measures
across cultural contexts, and this study reflects well the best
practices for developing a relevant survey tool for use in the
four intended countries (44). For instance, bilingual researchers
from each of the four cultural perspectives, as well as public
health practitioners working in the chronic disease prevention
context in each country were involved in the development
of the questions, response options, translations, and reliability
testing. Despite steps that the research team took to minimize
mis-translation, the meaning of each question and response
option becomes one layer removed from its original, intended
meaning after translation. Next steps for informing further
adaptation of the survey tool should include validity testing
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TABLE 2 | Frequency of response option endorsement by country (N = 165).
Question and response options

Australia
(Total N = 39)

Brazil
(Total N = 27)

China
(Total N = 45)

United States
(Total N = 54)

N (%)

N (%)

N (%)

N (%)

Not at all knowledgeable

0 (0.0)

0 (0.0)

7 (15.6)

0 (0.0)

Slightly knowledgeable

0 (0.0)

1 (3.7)

15 (33.3)

1 (1.9)

1. How knowledgeable are you with evidence-based processes?

Somewhat knowledgeable

9 (23.1)

8 (29.6)

16 (35.6)

6 (11.1)

Moderately knowledgeable

22 (56.4)

13 (48.1)

8 (17.8)

31 (57.4)

Extremely knowledgeable

8 (20.5)

5( 18.5)

1 (2.2)

16 (29.6)

2. I have used repositories to find evidence-based interventions:
In none of my programmatic areas

2 (5.1)

0 (0.0)

12 (26.7)

3 (5.6)

In a few of my programmatic areas

11 (28.2)

7 (25.9)

25 (55.6)

18 (33.3)

In many of my programmatic areas

16 (41.0)

7 (25.9)

6 (13.3)

27 (50.0)

In all of my programmatic areas

8 (20.5)

13 (48.1)

1 (2.2)

5 (9.3)

I don’t know

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Not applicable

2 (5.13)

0 (0.0)

3 (6.7)

1 (1.9)

3. Staff at my agency use repositories of evidence-based interventions:
In none of their programmatic areas

0 (0.0)

0 (0.0)

11 (24.4)

2 (3.7)

In a few of their programmatic areas

9 (23.1)

5 (18.5)

19 (42.2)

18 (33.3)

In many of their programmatic areas

19 (48.7)

11 (40.7)

8 (17.8)

24 (44.4)

In all of their programmatic areas

4 (10.3)

9 (33.3)

0 (0.0)

1 (1.9)

I don’t know

3 (7.7)

1 (3.7)

9 (20.0)

7 (13.0)

Not applicable

3 (7.7)

1 (3.7)

0 (0.0)

2 (3.7)

24 (44.4)

4. When you make decisions about such things as program
planning and implementation, policy development, or funding,
which of the following are important to you?
Support from leadership at my agency

9 (23.1)

22 (81.5)

31 (68.9)

Support from elected officials

5 (12.8)

13 (48.1)

17 (37.8)

4 (7.4)

Support from community partnerships

13 (33.3)

20 (74.1)

16 (35.6)

21 (38.9)

1 (2.6)

17 (63.0)

10 (22.2)

16 (29.6)

Recommendations from the funding agency/ Recommendations
from the Research Management Department (China)
Colleagues are using the intervention
Available resources (program dollars and staff)
How easy the intervention or policy is to implement

1 (2.6)

19 (70.4)

6 (13.3)

1 (1.9)

15 (38.5)

26 (96.3)

25 (55.6)

36 (66.7)

2 (5.1)

12 (44.4)

23 (51.1)

1 (1.9)

30 (76.9)

23 (85.2)

13 (28.9)

32 (59.3)

5 (12.8)

21 (77.8)

9 (20.0)

1 (1.9)

Relevance of the intervention to the population of interest

26 (66.7)

24 (88.9)

18 (40.0)

20 (37.0)

Seriousness of the health problem

9 (23.1)

20 (74.1)

9 (20.0)

5 (9.3)

Other

1 (2.6)

0 (0.0)

0 (0.0)

1 (1.9)

Not applicable

0 (0.0)

0 (0.0)

1 (2.2)

0 (0.0)

Evidence regarding the effectiveness of the intervention
Health planning tools (e.g. MAPP or Health People
2010)/Government Health plans (China)

5. What avenues do you use to learn about the current study
findings on evidence-based chronic disease
prevention interventions?
Academic journals

36 (92.3)

19 (70.4)

23 (51.1)

24 (44.4)

Conferences

35 (89.7)

14 (51.9)

14 (31.1)

36 (66.7)

Email alerts

28 (71.8)

5 (18.5)

5 (11.1)

32 (59.3)

Evidence-based repositories

17 (43.6)

19 (70.4)

8 (17.8)

31 (57.4)

Facebook/Weibo, Wechat (China)

4 (10.3)

1 (3.7)

10 (22.2)

4 (7.4)

Fundersa

4 (10.3)

0 (0.0)

–

23 (42.6)

Government agency staff

12 (30.8)

17 (63.0)

2 (4.4)

25 (46.3)
(Continued)
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TABLE 2 | Continued
Question and response options

Australia
(Total N = 39)

Brazil
(Total N = 27)

China
(Total N = 45)

United States
(Total N = 54)

N (%)

N (%)

N (%)

N (%)

Government reports

23 (59.0)

23 (85.2)

3 (6.7)

23 (42.6)

Internet search engines

21 (53.8)

16 (59.3)

14 (31.1)

32 (59.3)

Listservs/Newsletters/Online forums

15 (38.5)

2 (7.4)

3 (6.7)

25 (46.3)

Media campaigns/Media interviews

4 (10.3)

3 (11.1)

6 (13.3)

7 (13.0)

Networks

23 (59.0)

10 (37.0)

5 (11.1)

18 (33.3)

26 (66.7)

14 (51.9)

7 (15.6)

35 (64.8)

Policy briefsa

11 (28.2)

12 (44.4)

–

17 (31.5)

Press releases

8 (20.5)

3 (11.1)

6 (13.3)

9 (16.7)

Stakeholdersa

11 (28.2)

27 (100.0)

–

14 (25.9)
21 (38.9)

Partnerships (e.g., with universities, health departments,
professional associations)

Technical assistance/Data liaison

1 (2.6)

13 (48.1)

2 (4.4)

Trainings/Workshops/Meetings within my agency

17 (43.6)

11 (40.7)

18 (40.0)

7 (13.0)

Webinars

16 (41.0)

2 (7.4)

1 (2.2)

36 (66.7)

Other

0 (0.0)

2 (7.4)

0 (0.0)

1 (1.9)

None

1 (2.6)

1 (3.7)

5 (11.1)

0 (0.0)

6. For which avenues would you like additional access?
Academic journals

12 (30.8)

16 (59.3)

17 (37.8)

12 (22.2)

Conferences

8 (20.5)

17 (63.0)

10 (22.2)

16 (29.6)

Email alerts

3 (7.7)

5 (18.5)

10 (22.2)

4 (7.4)

13 (33.3)

7 (25.9)

19 (42.2)

18 (33.3)

Evidence-based repositories
Facebook/Weibo, Wechat (China)

2 (5.1)

2 (7.4)

12 (26.7)

3 (5.6)

Fundersa

4 (10.3)

3 (11.1)

–

10 (18.5)

Government agency staff

6 (15.4)

2 (7.4)

2 (4.4)

6 (11.1)

Government reports

8 (20.5)

5 (18.5)

8 (17.8)

3 (5.6)

Internet search engines

1 (2.6)

2 (7.4)

11 (24.4)

3 (5.6)

Listservs/Newsletters/Online forums

4 (10.3)

3 (11.1)

14 (31.1)

8 (14.8)

Media campaigns/Media interviews

2 (5.1)

1 (3.7)

4 (8.9)

4 (7.4)

Networks

9 (23.1)

6 (22.2)

2 (4.4)

8 (14.8)

13 (33.3)

11 (40.7)

13 (28.9)

15 (27.8)

Partnerships (e.g., with universities, health departments,
professional associations)
Policy briefs

5 (12.8)

2 (7.4)

0 (0.0)

4 (7.4)

Press releases

2 (5.1)

2 (7.4)

7 (15.6)

2 (3.7)

Stakeholdersa

4 (10.3)

2 (7.4)

–

3 (5.6)

Technical assistance/Data liaison

6 (15.4)

1 (3.7)

9 (20.0)

12 (22.2)

Trainings/Workshops/Meetings within my agency

8 (20.5)

10 (37.0)

18 (40.0)

12 (22.2)

Webinars

10 (25.6)

1 (3.7)

3 (6.7)

9 (16.7)

Other

3 (7.7)

0 (0.0)

0 (0.0)

0 (0.0)

None

1 (2.6)

0 (0.0)

3 (6.7)

0 (0.0)

Questions 7 and 8 N/A
9. Staff at my agency use quality improvement processes:
In none of their programmatic areas

0 (0.0)

1 (3.7)

9 (20.0)

0 (0.0)

In a few of their programmatic areas

10 (25.6)

8 (29.6)

16 (35.6)

20 (37.0)

In many of their programmatic areas

16 (41.0)

12 (44.4)

15 (33.3)

28 (51.9)

In all of their programmatic areas

8 (20.5)

5 (18.5)

1 (2.2)

4 (7.4)

I don’t know

3 (7.7)

1 (3.7)

5 (11.1)

1 (1.9)

Not applicable

2 (5.1)

0 (0.0)

0 (0.0)

1 (1.9)

2 (5.1)

21 (77.8)

21 (46.7)

0 (0.0)

10. In your opinion, how often do programs end that should
have continued?
Never

(Continued)
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TABLE 2 | Continued
Question and response options

Australia
(Total N = 39)

Brazil
(Total N = 27)

China
(Total N = 45)

United States
(Total N = 54)

N (%)

N (%)

N (%)

N (%)

Sometimes

15 (38.5)

2 (7.4)

2 (4.4)

28 (51.9)

Often

20 (51.3)

3 (11.1)

19 (42.2)

24 (44.4)

11. When you think about public health programs that have
ended, what are the most common reasons for programs ending?
Program was never evaluated

9 (23.1)

9 (33.3)

3 (6.7)

9 (16.7)

Program was evaluated but did not demonstrate impact

12 (30.8)

8 (29.6)

16 (35.6)

7 (13.0)

Opposition/lack of support from leaders in my agency

7 (17.9)

10 (37.0)

8 (17.8)

6 (11.1)

Opposition/lack of support from the general public

1 (2.6)

6 (22.2)

20 (44.4)

6 (11.1)

10 (25.6)

8 (29.6)

10 (22.2)

10 (18.5)

Opposition/lack of support from policy makers
Funding diverted to a higher priority program

11 (28.2)

13 (48.1)

12 (26.7)

20 (37.0)

Grant funding ended

25 (64.1)

14 (51.9)

12 (26.7)

46 (85.2)

Change in political leadership

17 (43.6)

15 (55.6)

3 (6.7)

4 (7.4)

1 (2.6)

4 (14.8)

0 (0.0)

6 (11.1)

Insurance funding/coverage ended
Program was adopted or continued by other organizations

0 (0.0)

1 (3.7)

0 (0.0)

8 (14.8)

A program champion departed

9 (23.1)

9 (33.3)

3 (6.7)

1 (1.9)

Program was not evidence-based

1 (2.6)

7 (25.9)

5 (11.1)

3 (5.6)

Program was expensive

1 (2.6)

4 (14.8)

8 (17.8)

11 (20.4)

Program was challenging to maintain

2 (5.1)

4 (14.8)

24 (53.3)

2 (3.7)

Other, please specify ______

2 (5.1)

0 (0.0)

1 (2.2)

2 (3.7)

I do not know

0 (0.0)

0 (0.0)

4 (8.9)

1 (1.9)

Not applicable

1 (2.6)

1 (3.7)

0 (0.0)

5 (9.3)

12. In your opinion, how often do programs continue that should
have ended?
1 (2.6)

4 (14.8)

19 (42.2)

0 (0.0)

Sometimes

Never

20 (51.3)

21 (77.8)

2 (4.4)

35 (64.8)

Often

10 (25.6)

2 (7.4)

22 (48.9)

13 (24.1)

13. When you think about public health programs that continued
that should have ended, what are the most common reasons for
their continuation?
Program was never evaluated

12 (30.8)

7 (25.9)

6 (13.3)

9 (16.7)

Sustained support from leaders in your agency

13 (33.3)

6 (22.2)

14 (31.1)

16 (29.6)

Sustained support from the general public

6 (15.4)

5 (18.5)

17 (37.8)

8 (14.8)

Sustained support from policymakers

11 (28.2)

12 (44.4)

15 (33.3)

21 (38.9)

Prohibitive costs of starting something new

9 (23.1)

4 (14.8)

5 (11.1)

5 (9.3)

Absence of alternative options

9 (23.1)

7 (25.9)

13 (28.9)

9 (16.7)

Sustained funding

7 (17.9)

12 (44.4)

14 (31.1)

26 (48.1)

Presence of a program champion

12 (30.8)

7 (25.9)

5 (11.1)

13 (24.1)

Program was considered evidence-based

4 (10.3)

2 (7.4)

9 (20.0)

5 (9.3)

Program was low-cost

9 (23.1)

6 (22.2)

5 (11.1)

11 (20.4)

Program was easy to maintain

10 (25.6)

6 (22.2)

12 (26.7)

15 (27.8)

Other, please specify ______

4 (10.3)

1 (3.7)

0 (0.0)

4 (7.4)

I do not know

0 (0.0)

3 (11.1)

5 (11.1)

1 (1.9)

Not applicable

2 (5.1)

0 (0.0)

3 (6.7)

0 (0.0)

12 (22.2)

14. Which of the following are personal barriers that make it harder
for you to select and implement evidence-based chronic disease
prevention interventions?
Not being an expert on relevant issues

10 (25.6)

5 (18.5)

29 (64.4)

Lack of confidence in finding data and statistics

7 (17.9)

1 (3.7)

10 (22.2)

6 (11.1)

Lack of skills to develop evidence-based interventions

6 (15.4)

6 (22.2)

18 (40.0)

8 (14.8)
(Continued)
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TABLE 2 | Continued
Question and response options

Lack of confidence in carrying out evidence-based interventions

Australia
(Total N = 39)

Brazil
(Total N = 27)

China
(Total N = 45)

United States
(Total N = 54)

N (%)

N (%)

N (%)

N (%)

3 (7.7)

1 (3.7)

7 (15.6)

3 (5.6)

23 (59.0)

8 (29.6)

20 (44.4)

15 (27.8)

Low value of evidence-based approaches

5 (12.8)

13 (48.1)

0 (0.0)

1 (1.9)

Workload is too heavy/not enough time

19 (48.7)

5 (18.5)

19 (42.2)

33 (61.1)

Overwhelmed by task

5 (12.8)

6 (22.2)

6 (13.3)

11 (20.4)

Other

8 (20.5)

1 (3.7)

1 (2.2)

12 (22.2)

None

2 (5.1)

0 (0.0)

0 (0.0)

5 (9.3)

Lack of decision-making authority

15. Which of the following are agency-level barriers that make it
harder for you to select and implement evidence-based chronic
disease prevention interventions?
Poor understanding of evidence-based approaches

6 (15.4)

5 (18.5)

4 (8.9)

12 (22.2)

Culture/climate is not supportive of change/new ideas

14 (35.9)

3 (11.1)

1 (2.2)

20 (37.0)

No existing policies to support evidence-based approaches

5 (12.8)

4 (14.8)

14 (31.1)

9 (16.7)

Agency does not provide training in evidence-based approaches

9 (23.1)

10 (37.0)

5 (11.1)

10 (18.5)

Staff/leaders lack formal training in evidence-based approaches

12 (30.8)

7 (25.9)

13 (28.9)

14 (25.9)

Lack of access to resources (e.g., computer, Internet)

4 (10.3)

3 (11.1)

14 (31.1)

3 (5.6)

Not enough funding

22 (56.4)

13 (48.1)

13 (28.9)

40 (74.1)

Low priority placed on chronic disease prevention

5 (12.8)

5 (18.5)

4 (8.9)

12 (22.2)

No systems to ensure interventions are evidence-based

8 (20.5)

16 (59.3)

11 (24.4)

15 (27.8)

Not enough staff

11 (28.2)

4 (14.8)

17 (37.8)

30 (55.6)

4 (10.3)

2 (7.4)

4 (8.9)

4 (7.4)

Beliefs that evidence-based interventions are too difficult to
implement/sustain
Other

6 (15.4)

0 (0.0)

0 (0.0)

2 (3.7)

None

3 (7.7)

0 (0.0)

3 (6.7)

3 (5.6)

16. Which of the following are community-level barriers that make
it harder for you to select and implement evidence-based chronic
disease prevention interventions?
Lack of access to repositories/databases of scientific studies

7 (17.9)

4 (14.8)

37 (82.2)

7 (13.0)

Lack of partnership between agency and community

13 (33.3)

4 (14.8)

6 (13.3)

13 (24.1)

22 (56.4)

8 (29.6)

20 (44.4)

30 (55.6)

Community members’ needs compete with evidence-based
recommendations
Catering to preferences of fundersa

17 (43.6)

3 (11.1)

–

25 (46.3)

Low priority placed on chronic disease prevention

11 (28.2)

14 (51.9)

7 (15.6)

15 (27.8)

Other

4 (10.3)

1 (3.7)

0 (0.0)

6 (11.1)

None

1 (2.6)

7 (25.9)

3 (6.7)

4 (7.4)

17. Which of the following are sociocultural barriers that make it
harder for you to select and implement evidence-based chronic
disease prevention interventions?
Distrust of scientific data in the populations served

2 (5.1)

5 (18.5)

7 (15.6)

13 (24.1)

20 (51.3)

9 (33.3)

13 (28.9)

19 (35.2)

Not enough relevant evidence for populations served

18 (46.2)

5 (18.5)

25 (55.6)

14 (25.9)

Serving a rural setting where data are lackinga

15 (38.5)

3 (11.1)

–

34 (63.0)

Serving a highly disadvantaged population

18 (46.2)

7 (25.9)

10 (22.2)

21 (38.9)

7 (17.9)

1 (3.7)

–

8 (14.8)
2 (3.7)

Community cultural practices conflict with evidence-based
recommendations

Serving a population that speaks a language different from the
majoritya
Evidence is presented in a language I do not understand

0 (0.0)

1 (3.7)

6 (13.3)

Other

1 (2.6)

8 (29.6)

1 (2.2)

2 (3.7)

None

3 (7.7)

2 (7.4)

4 (8.9)

4 (7.4)
(Continued)
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TABLE 2 | Continued
Question and response options

Australia
(Total N = 39)

Brazil
(Total N = 27)

China
(Total N = 45)

United States
(Total N = 54)

N (%)

N (%)

N (%)

N (%)

18. Which of the following are political/economic barriers that
make it harder for you to select and implement evidence-based
chronic disease prevention interventions?
Political leaders not providing enough support

24 (61.5)

10 (37.0)

26 (57.8)

21 (38.9)

Funding changes that occur with changes in political leadership

33 (84.6)

12 (44.4)

13 (28.9)

31 (57.4)

Political climate conflicts with evidence-based chronic disease
prevention recommendations

21 (53.8)

2 (7.4)

16 (35.6)

25 (46.3)

Health care system does not support evidence-based chronic
disease prevention

15 (38.5)

5 (18.5)

3 (6.7)

15 (27.8)

Other

5 (12.8)

3 (11.1)

0 (0.0)

2 (3.7)

None

1 (2.6)

0 (0.0)

12 (26.7)

5 (9.3)

19. For which of the following skills would you like additional
technical support or training:
Prioritizing program and policy options

6 (15.4)

17 (63.0)

20 (44.4)

16 (29.6)

Quantifying the public health issue using descriptive
epidemiology (e.g., concepts of person, place, time)

22 (56.4)

14 (51.9)

15 (33.3)

21 (38.9)

Using quantitative evaluation approaches (e.g., surveillance or
surveys)

18 (46.2)

4 (14.8)

14 (31.1)

20 (37.0)

Using qualitative evaluation approaches (e.g., focus groups, key
informant interviews)

15 (38.5)

6 (22.2)

11 (24.4)

19 (35.2)

Developing an action plan for achieving goals

13 (33.3)

13 (48.1)

19 (42.2)

17 (31.5)

12 (30.8)

17 (63.0)

26 (57.8)

27 (50.0)

Adapting interventions for different communities and settings

16 (41.0)

16 (59.3)

12 (26.7)

29 (53.7)

Using economic data in the decision making process

21 (53.8)

12 (44.4)

16 (35.6)

22 (40.7)

Communicating research to policy makers

20 (51.3)

8 (29.6)

15 (33.3)

23 (42.6)

Other

1 (2.6)

0 (0.0)

1 (2.2)

1 (1.9)

None

1 (2.6)

7 (25.9)

3 (6.7)

2 (3.7)

Defining the health issue according to the community’s needs
and assets

a This

item was not applicable and not included in the survey for respondents in China.

order to better facilitate the sustainability of interventions (47).
The questions within this survey tool reflect critical contextual
factors based on the literature, qualitative interviews of public
health practitioners, and expert review (2, 5, 6). This survey
tool allows researchers to proceed with research on the D&I of
EBCDP interventions on a more global scale than was previously
available. To our knowledge, this is the first study of its kind
that used common methods across four countries. The research
team had particular trouble recruiting retest respondents in
Brazil due to significant political unrest that affected public
health practitioners at the time of the request (39, 40). This
contributed to the longer duration between test and retest and
the smaller sample from Brazil compared with the other three
countries. Additionally, his survey tool demonstrated lower
reliability of responses among practitioners from Brazil and
China compared with those from Australia and the United States.
Lastly, a convenience sampling approach was carried out in
some of the countries to recruit chronic disease prevention
practitioners serving local or regional jurisdictions. Such a
sampling method introduces potential selection bias and is
unlikely to produce representative samples of all chronic disease
prevention practitioners in each country. However, the intention

among chronic disease prevention practitioners in Australia,
Brazil, China, and the United States, ideally in representative
samples (45).
There was low prevalence (N < 5) for many response options
and the items with low prevalence varied by country. According
to Sim and Wright, low prevalence has stifling effects on Cohen’s
kappa coefficients, but inflating effects on percentage agreement
(46). Low prevalence likely contributed to the low kappa
coefficients and comparatively higher percentage agreement
found in this study. A larger sample of practitioners across all four
countries with more diversity of experiences may improve the
variability of responses and the accuracy of reliability findings.
Response items with low prevalence of endorsements may also
reflect response items that are less applicable to practitioners’
experiences in that particular country. Use of this survey tool in a
larger, randomly selected sample of chronic disease practitioners
in each country would clarify this conjecture.

Strengths and Limitations
This study responds well to a U.S. federal report that called for
additional research focused on the experiences and perspectives
of key stakeholders in evidence-based intervention delivery, in
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TABLE 3 | Test-retest percent agreement and reliability coefficients by question and country (N = 165).
Questions

Australia
(N = 39)
%a

Brazil
(N = 27)

China
(N = 45)

ICCb,c

%

ICC

%

United States
(N = 54)
ICC

%

ICC

Personal knowledge of evidence-based processes

0.564

0.570

0.667

0.003

0.467

0.511

0.660

0.658

Personal use of repositories to find evidence-based
interventions

0.583

0.544

0.630

0.594

0.512

−0.007

0.571

0.508

Workplace staff use of repositories to find
evidence-based interventions

0.828

0.762

0.539

0.264

0.576

0.374

0.643

0.515

Percentage workplace programs are evidence-based

–

0.731

–

0.566

–

0.797

–

0.797

Workplace staff use of quality improvement processes

0.581

0.422

0.539

0.423

0.600

0.601

0.600

0.544

Frequency that programs end that should have
continued

0.714

0.297

0.444

0.219

0.480

0.174

0.792

0.585

Frequency that programs continue that should have
ended

0.828

0.569

0.682

0.116

0.346

−0.094

0.800

0.475

Mean
%

Mean
Kappad

Mean
%

Mean
Kappa

Mean
%

Mean
Kappa

Mean
%

Mean
Kappa

Important factors in decision-making related to program
planning and implementation, policy development, or
funding

0.811

0.305

0.768

0.416

0.739

0.311

0.772

0.361

Avenues used to learn about evidence-based chronic
disease prevention interventions

0.774

0.402

0.702

0.297

0.804

0.225

0.786

0.408
0.177

Avenues for which additional access is needed

0.810

0.214

0.763

0.154

0.800

0.252

0.778

Most common reasons for program termination

0.824

0.203

0.693

0.203

0.745

0.179

0.840

0.269

Most common reasons for program continuation

0.758

0.258

0.684

0.219

0.733

0.133

0.754

0.249

Personal barriers to selecting and implementing
evidence-based chronic disease prevention interventions

0.823

0.379

0.810

0.308

0.749

0.336

0.857

0.376

Organizational barriers to selecting and implementing
evidence-based chronic disease prevention interventions

0.783

0.279

0.790

0.362

0.794

0.260

0.838

0.462

Community-level barriers to selecting and implementing
evidence-based chronic disease prevention interventions

0.747

0.235

0.763

0.337

0.836

0.367

0.798

0.387

Sociocultural barriers to selecting and implementing
evidence-based chronic disease prevention interventions

0.756

0.286

0.806

0.353

0.808

0.433

0.848

0.476

Political/economic barriers to selecting and
implementing evidence-based chronic disease
prevention interventions:

0.763

0.204

0.778

0.391

0.747

0.267

0.782

0.329

Skills for which additional technical support or training is
needed

0.764

0.466

0.619

0.191

0.687

0.257

0.736

0.273

a %,

Percent agreement. b ICC, Intraclass correlation coefficient. c Survey questions with ordinal response options were assessed using ICC. d Survey questions with a list of response
options had each response option dichotomized into selected or not selected, then assessed using Cohen’s kappa, and the mean kappa for each set of response options is reported.

the creation of multi-level strategies and policies that promote
evidence-based decision-making and effective prevention of
chronic diseases on a global scale.

of the present study was not to test hypotheses or provide
prevalence estimates, which would have required using methods
to address sampling error (46). Acknowledging these limitations
of the sampling approach, the researcher team ensured that the
selected sample included practitioners from various regions of
each country, and provided distributions of all survey responses
as well as demographic characteristics of the sample.

ETHICS STATEMENT
This study was carried out in accordance with the committee
responsible for human experimentation (institutional and
national) and with the World Medical Association’s Declaration
of Helsinki with informed consent from all subjects. After reading
the electronic informed consent document, subjects indicated
their consent by selecting a radial button at the bottom of the
informed consent document that read, I consent to participate in
this research study. Additional written documentation of consent
was waived and the protocol was approved by The University

CONCLUSION
This survey tool allows cross-country data collection that can
contribute toward an improved understanding of the contextual
factors that public health practitioners in Australia, Brazil,
China, and the United States face in their daily chronic
disease prevention work. This understanding is necessary for
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